Phenolic Compounds from the Aerial Parts of Adenophora triphylla (Thunb.) A. DC. var. triphylla and their Free Radical Scavenging Activity

Adenophora triphylla (Thunb.) A. DC. var. triphylla (Family: Campanulaceae) is distributed in Japan, Korea, and China. It is locally known as “Saiyousyajin” in Japan and the roots are used in traditional medicine to treat chronic bronchitis and whooping cough, and also as anti-inflammatory and anti-tussive agents. Till now, there is no report on the chemical constituents of aerial parts. Thus, the main aim of this study was to isolate and identify major chemical constituents of aerial parts of A. triphylla var. triphylla, and to evaluate their free radical scavenging activity. The 70% methanol extract of the aerial parts was subjected to repeated column chromatography using MCI gel CHP-20P, Sephadex LH-20, ODS and silica gel columns to isolate the five phenolic components (1-5). Free radical scavenging activity of the extract and compounds was evaluated using 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical scavenging activity method. The structures of the isolated compounds were elucidated as luteolin (1), luteolin 4’-O-b-glucopyranoside (2), luteolin 7-O-b-glucopyranoside (3), luteolin 7-O-neohesperidoside (4) and chlorogenic acid (5) based on their nuclear magnetic resonance (NMR) spectral data and comparison with literature values. All these compounds were isolated for the first time from A. triphylla var. triphylla. Extract showed weak free radical scavenging activity. Among isolated compounds, luteolin (1), luteolin 7-O-b-glucopyranoside (3), luteolin 7-O-neohesperidoside (4) and chlorogenic acid (5) showed potent free radical scavenging activity. Results from this study suggest that the aerial parts of A. triphylla var. triphylla might be a potential plant source for the development of functional foods, however further detailed research is necessary

Identification of the catalytic subunit of cAMP-dependent protein kinase from the photosynthetic flagellate, Euglena gracilis Z11The nucleotide sequence data reported in this paper will appear in the DDBJ/EMBL/GenBank nucleotide sequence databases with the accession number AB021126.

AbstractA gene named epk2 that encodes the amino acid sequence of a protein kinase was identified from the photosynthetic flagellate, Euglena gracilis Z. Homology search and phylogenetic analysis revealed that the deduced amino acid sequence of epk2 is most similar to that of the catalytic subunit of cAMP-dependent protein kinase (PKA). Northern blot analysis showed that Euglena cells express a 1.4-kb transcript of this gene. When the EPK2 protein was coexpressed with the rat regulatory subunit of PKA in cultured mammalian cells, these two proteins were coimmunoprecipitated. The association of EPK2 and the rat regulatory subunit of PKA was not detected in the cell lysate incubated with cAMP. EPK2 immunoprecipitated from the transfected cells phosphorylated Kemptide, a synthetic peptide substrate for PKA, and the phosphorylation was inhibited by PKI, a PKA-selective protein kinase inhibitor. These results indicate that EPK2 is a PKA homologue in the photosynthetic flagellate, and this is the first evidence for the occurrence of the PKA catalytic subunit in photosynthetic organisms

Phenolic Acid Derivatives, Flavonoids and Other Bioactive Compounds from the Leaves of Cardiocrinum cordatum (Thunb.) Makino (Liliaceae)

Cardiocrinum cordatum (Thunb.) Makino (Family: Liliaceae), commonly known as ‘Ubayuri’, is native to Japan and some islands in the Russian Far East. It has high value as food, medicinal, and ornamental species. The aim of this study was to isolate and characterize the main chemical constituents of the leaves of C. cordatum. A total of 19 compounds, namely caffeic acid (1), caffeic acid methyl ester (2), caffeic acid β-glucopyranosyl ester (3), caffeic acid 4-O-β-glucopyranoside (4), ferulic acid (5), isoferulic acid (6), protocatechuic acid (7), syringic acid (8), 2,6-dimethoxy-p-hydroquinone 1-O-β-glucopyranoside (9), esculetin (10), taxifolin (11), quercetin 3-O-(6-O-α-rhamnopyranosyl)β-glucopyranoside-7-O-β-rhamnopyranoside (12), 2,7-dimethyl-2,4-diene-deca-α,ω-diacid β-glucopyranoside (13), 4-[formyl-5-(methoxymethyl)-1H-pyrrol-1-yl]butanoic acid (14), (3Z)-3-hexenyl β-glucopyranoside (15), tryptophan (16), adenine (17), adenosine (18), and 2-deoxyadenosine (19) were isolated using various chromatographic methods. The structures of isolated compounds were elucidated on the basis of their NMR spectroscopic data. All these compounds were isolated for the first time from the genus Cardiocrinum. Phenolic acid derivatives and flavonoids can be considered as chemotaxonomic markers in the leaves of Cardiocrinum species

Primary Motor Cortex Activation during Action Observation of Tasks at Different Video Speeds Is Dependent on Movement Task and Muscle Properties

The aim of the present study was to investigate how the video speed of observed action affects the excitability of the primary motor cortex (M1), as assessed by the size of motor-evoked potentials (MEPs) induced by transcranial magnetic stimulation (TMS). Twelve healthy subjects observed a video clip of a person catching a ball (Experiment 1: rapid movement) and another 12 healthy subjects observed a video clip of a person reaching to lift a ball (Experiment 2: slow movement task). We played each video at three different speeds (slow, normal and fast). The stimulus was given at two points of timing in each experiment. These stimulus points were locked to specific frames of the video rather than occurring at specific absolute times, for ease of comparison across different speeds. We recorded MEPs from the first dorsal interosseous muscle (FDI) and abductor digiti minimi muscle (ADM) of the right hand. MEPs were significantly different for different video speeds only in the rapid movement task. MEPs for the rapid movement task were higher when subjects observed an action played at slow speed than normal or fast speed condition. There was no significant change for the slow movement task. Video speed was effective only in the ADM. Moreover, MEPs in the ADM were significantly higher than in the FDI in a rapid movement task under the slow speed condition. Our findings suggest that the M1 becomes more excitable when subjects observe the video clip at the slow speed in a rapid movement, because they could recognize the elements of movement in others. Our results suggest the effects of manipulating the speed of the viewed task on the excitability of the M1 during passive observation differ depending on the type of movement task observed. It is likely that rehabilitation in the clinical setting will be more efficient if the video speed is changed to match the task\u27s characteristics

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo